Squarepoint’s Vera Therapeutics VERA Stock Holding History

Squarepoint’s Portfolio VERA Stock Details VERA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$631K	Buy	+15,684	New	+$676K	﹤0.01%	3150
2025 Q3	–	Sell	-57,519	Closed	-$1.36M	–	5043
2025 Q2	$1.36M	Buy	57,519 +40,196	+232%	+$904K	﹤0.01%	2396
2025 Q1	$416K	Buy	+17,323	New	+$557K	﹤0.01%	3471
2024 Q4	–	Sell	-70,416	Closed	-$3.11M	–	5535
2024 Q3	$3.11M	Sell	70,416 -77,595	-52%	-$2.94M	﹤0.01%	1756
2024 Q2	$5.36M	Buy	148,011 +112,475	+317%	+$4.46M	0.01%	1326
2024 Q1	$1.53M	Buy	35,536 +17,148	+93%	+$611K	﹤0.01%	2278
2023 Q4	$283K	Buy	+18,388	New	+$234K	﹤0.01%	3402
2023 Q2	–	Sell	-66,116	Closed	-$513K	–	4047
2023 Q1	$513K	Buy	+66,116	New	+$510K	﹤0.01%	2286

Other funds holding VERA

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Squarepoint's VERA Position: Q1 2026 in Review

Squarepoint opened a new position in Vera Therapeutics (VERA) in Q1 2026: 15,684 shares worth $631K. The stake represents ﹤0.01% of the portfolio and ranks #3150 among its holdings. This is a return to the name: Squarepoint previously reported a position in VERA as recently as Q2 2025.

Squarepoint first reported a position in VERA in Q1 2023 and has held it in 8 quarters since. The position peaked at $5.36M in Q2 2024. 229 funds tracked by Wall St. Rank hold VERA as of Q1 2026.

Squarepoint held 15,684 shares of Vera Therapeutics worth $631K as of Q1 2026.
Vera Therapeutics was a new Squarepoint position in Q1 2026.
Vera Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3150 holding.
Squarepoint first reported a position in Vera Therapeutics in Q1 2023 and has held it in 8 quarters since.
Squarepoint's Vera Therapeutics position peaked at $5.36M in Q2 2024.
229 funds tracked by Wall St. Rank held Vera Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.